17th Sep 2025 07:00
Tissue Regenix Group plc
('Tissue Regenix' or the 'Group')
Notice of Results
Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms that further to the announcement on 8 September 2025, the Company will now issue its interim results on Tuesday 30 September.
Investor Briefing
Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4pm BST on Tuesday 30 September. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.
For more information:
Tissue Regenix Group plc | www.tissueregenix.com |
Daniel Lee, Chief Executive Officer Brandon Largent, Interim Chief Financial Officer | via Walbrook PR |
Cavendish Capital Markets Limited (Nominated Adviser and Broker) | |
Geoff Nash/Giles Balleny/Edward Whiley | Tel: +44 (0) 20 7466 5000 |
Nigel Birks - Life Science Specialist Sales | |
Harriet Ward - ECM | |
| |
Walbrook PR (Financial PR and IR) | Tel: +44 (0)20 7933 8780 |
Alice Woodings | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.
Related Shares:
Tissue Regenix Group